logo

health care News

Share

Intercept Pharma Says REVERSE Phase 3 Study Of Obeticholic Acid Fails To Meet Primary Endpoint

Biogen: European Medicines Agency Accepts Marketing Authorization Application For BIIB800

Zealand Pharma Announces Positive Results From Phase 3 Trial Of Glepaglutide In Patients With Short Bowel Syndrome

Moderna Expands Executive Committee To Prepare For Multiple Upcoming New Product Launches

Sarepta Therapeutics Submits BLA For SRP-9001 For Ambulant Patients With Duchenne Muscular Dystrophy

Celadon Pharma H1 Loss Per Share 25.1p Vs Loss 4.4p Last Year

KemPharm Announces Positive Topline Data From Phase 1 Trial Evaluating Cardiovascular Safety Of Serdexmethylphenidate

Cara Therapeutics Submits NDA In Japan For Approval Of Difelikefalin For Pruritus In Hemodialysis

Revive Therapeutics Provides Update On Phase 3 Clinical Trial For Bucillamine In COVID-19